Cenicriviroc mesylate/Tropifexor

N/A

Report date: 2024/01/16 15:43:30

Base Information

Drug NameCenicriviroc mesylate/Tropifexor
Drug Alias NameCenicriviroc/TropifexorTropifexor/CenicrivirocTropifexor+Cenicriviroc mesylateCenicriviroc mesylate+TropifexorTropifexor/Cenicriviroc mesylate +[6] 
ClassificationSmall molecules
Mechanisms of ActionBile acid receptor FXR agonistsC-C chemokine receptor type 2 antagonistsC-C chemokine receptor type 5 antagonists
TargetsBile acid receptor FXRC-C chemokine receptor type 5C-C chemokine receptor type 2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes TropifexorCenicriviroc mesylate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesAllergan PlcNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A